A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

Also called NCT07796477

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT07796477
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07796477. Randomized; double masking; primary purpose treatment. Start 2026-11-06 (anticipated); primary completion 2027-09-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
SYH2069 Injection (group 1)
Intervention (Drug)
SYH2069 Injection (group 2)
Intervention (Drug)
SYH2069 Injection (group 3)
Intervention (Drug)
SYH2069 Injection (group 4)
Intervention (Drug)
SYH2069 Injection placebo
Intervention (Drug)
Tirzepatide Injection 15mg
Lead sponsor
CSPC Ouyi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07796477
Content hash
d2e86011e837f5477984345bf263c8970fad37f68824d2a71b4b7d301618c19c